


| Certificate of Mailing | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Date of Deposit <u>June 23, 2000</u> | Label Number: <u>EL623626196US</u> |
| I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Director for Patents and Trademarks, Washington, D.C. 20231 | |
| <u>James DeCamp</u> Printed name of person mailing correspondence |  Signature of person mailing correspondence |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Neil R. Cashman et al.

Art Unit:

Serial No.: Not Yet Assigned

Examiner:

Filed: June 23, 2000

Title: PRION PROTEIN PEPTIDES AND USES THEREOF

Director For Patents and Trademarks
Washington, D.C. 20231

STATEMENT UNDER 37 CFR §1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 CFR §§1.821 through 1.825 and consisting of 13 pages.

As required by 37 CFR § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 CFR §1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 CFR § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 CFR §1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 CFR §1.821(g), I hereby state that this submission contains no new matter.


If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 6/23/00


Karen L. Elbing, Ph.D.

Reg. No. 35,238


Reg. No. 43,580

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045